Hjem

Neurotargeting forskningsgruppe

Hovedinnhold

neurotargeting2024.png

The neurotargeting research group has a broad range of expertise. Advances in molecular neurobiology now provide possibilities for the development of new therapies designed for treatment of neurological and psychiatric disorders. This type of translational research requires competency in both basic molecular research and experience in practical treatment. 

The Neurotargeting Group constitutes one of three groups/labs in the Basic and Translational Neuroscience unit.

 

 

 

The group involves three principal investigators. Please visit their lab pages to learn more about their research.

 

Jan Haavik (Haavik lab)

Olga Therese Ousdal (Ousdal lab)

Emeritus Anni Vedeler (Vedeler lab)

Best 3-min presentation!
 José Miguel Godoy Munoz_Biocat

Nanobodies in Protein Science and Beyond

Congratulation to José Miguel Godoy who won the prizes for best 3-min presentation at the Biocat conference last week.

News
A woman standing by a clock

Rare genotype identified causing early menopause

A recent GWAS meta-analysis identified a rare genetic variant in the CCDC201 gene that causes women to experience menopause 9 years earlier, significantly impacting their reproductive health and fertility.

PhD defence
Tor Ivar Phd defence

Can kynurenine be used as a biomarker for ADHD and depression?

Tore Ivar Malmei Aarsland will defend his PhD degree at the University of Bergen on 21 May 2024 with the thesis "Tryptophan and kynurenine pathway metabolites in neuropsychiatric disorders".

Congrats
peter_defence.png

A new PhD!

Congratulations to Peter on becoming a PhD holder!

PhD defence
Peter Daniel Szigetvari

How is dopamine affected by neurometabolic diseases?

Peter Daniel Szigetvari will defend his PhD degree at the University of Bergen on 14 February 2024 with the thesis "Monoamine synthesis in neurometabolic disorders affecting catecholaminergic functioning".